These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

676 related items for PubMed ID: 12918067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C.
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [Abstract] [Full Text] [Related]

  • 3. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.
    J Natl Cancer Inst; 2004 Apr 21; 96(8):604-15. PubMed ID: 15100338
    [Abstract] [Full Text] [Related]

  • 4. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP.
    PLoS Med; 2006 May 21; 3(5):e138. PubMed ID: 16573364
    [Abstract] [Full Text] [Related]

  • 5. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J.
    Gynecol Obstet Fertil; 2006 Mar 21; 34(3):189-201. PubMed ID: 16529969
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S, Alain S, Denis F.
    Gynecol Obstet Fertil; 2006 Mar 21; 34(7-8):647-55. PubMed ID: 16807045
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J.
    Epidemiology; 2011 Jul 21; 22(4):505-15. PubMed ID: 21540743
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for cervical neoplasia in Denmark.
    Kjaer SK.
    APMIS Suppl; 1998 Jul 21; 80():1-41. PubMed ID: 9693662
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E.
    Lancet Oncol; 2005 May 21; 6(5):271-8. PubMed ID: 15863374
    [Abstract] [Full Text] [Related]

  • 13. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D.
    Gynecol Oncol; 2008 Sep 21; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [Abstract] [Full Text] [Related]

  • 14. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
    Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM.
    Eur J Gynaecol Oncol; 2005 Sep 21; 26(2):129-42. PubMed ID: 15857016
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M, Jasani B, Fiander A.
    Vaccine; 2007 Apr 20; 25(16):3007-13. PubMed ID: 17292517
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [Abstract] [Full Text] [Related]

  • 19. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.
    Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB.
    Am J Epidemiol; 2000 Jun 15; 151(12):1158-71. PubMed ID: 10905528
    [Abstract] [Full Text] [Related]

  • 20. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.